Krystal Biotech (NASDAQ:KRYS) Stock Price Expected to Rise, Citigroup Analyst Says

Krystal Biotech (NASDAQ:KRYS) had its target price hoisted by Citigroup from $206.00 to $215.00 in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Several other equities research analysts also recently weighed in on KRYS. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a report on Thursday. HC Wainwright restated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Wednesday. Finally, Chardan Capital lifted their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $210.00.

Krystal Biotech Stock Up 3.7 %

KRYS stock opened at $182.62 on Thursday. The stock has a market cap of $5.25 billion, a price-to-earnings ratio of 61.08 and a beta of 0.84. Krystal Biotech has a fifty-two week low of $107.50 and a fifty-two week high of $219.34. The business has a 50 day moving average price of $157.18 and a 200 day moving average price of $175.18.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The company had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm’s revenue for the quarter was up 116.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.30 earnings per share. As a group, sell-side analysts anticipate that Krystal Biotech will post 6.14 EPS for the current year.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 14.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB acquired a new position in shares of Krystal Biotech in the 3rd quarter valued at about $40,000. Values First Advisors Inc. acquired a new position in Krystal Biotech in the third quarter valued at approximately $53,000. GF Fund Management CO. LTD. bought a new position in shares of Krystal Biotech during the fourth quarter valued at approximately $95,000. Huntington National Bank raised its position in shares of Krystal Biotech by 97.6% during the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after purchasing an additional 283 shares during the period. Finally, Blue Trust Inc. raised its position in shares of Krystal Biotech by 242.4% during the 3rd quarter. Blue Trust Inc. now owns 582 shares of the company’s stock worth $107,000 after purchasing an additional 412 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).